Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 9Lung Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Fallopian Tube Neoplasms 1Extensive Stage Small Cell Lung Cancer 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Small Cell 1Carcinoma, Pancreatic Ductal 1Carcinoma, Neuroendocrine 1

Interventions

Cisplatin 6Etoposide 5Topotecan 4Carboplatin 4Pemetrexed 3Gemcitabine 3belinostat 2Temozolomide 2RRx-001 2vosaroxin 1vinflunine 1veliparib 1taxane 1sagopilone 1sacituzumab govitecan 1pembrolizumab 1lurtotecan 1liposomal doxorubicin 1enzalutamide 1bemiparin 1belotecan 1atezolizumab 1apalutamide 1alvocidib 1abiraterone 1Vinorelbine 1Tomography, X-Ray Computed 1Sorafenib 1Rhenium 1Radiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Small Cell × EC regimen × Thoracic × Clear all
NCT07625644 2026-06-04

Evaluate BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer

SystImmune Inc.

Phase 3 Not yet recruiting
550 enrolled
Thoracic

Lung Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡